#AVCT has that stream of news backed up. Why so quiet? Because they can be. Trust Shaun Chilton to handle this one impeccably.

#AVCT 👇🏻

#AVCT We need new SoC. Combo treatments improve patients lives. But don’t go far enough. AVA6000 raises the bar.

📣 #ESHMICRO2025 CALL FOR ABSTRACTS ➡ bit.ly/3VcfYKN 5th Scientific Workshop Tumour Microenvironment & its Therapeutic Targeting 🗓️ Feb. 16-18, 2025 in London 🇬🇧 Chairs: D. Bonnet, Nitin Jain, Marina Konopleva, D. S. Krause, S. Mendez-Ferrer, K. Yong UCLH #ESHCONFERENCES

#AVCT

#AVCT Patients: 46 Median prior treatment: 4 Safety profile: More than acceptable Efficacy: 1 partial response

#AVCT Fantastic and candid ADC article. “Even with the exact same antibody and payload, if you change the linker, you get a completely different outcome.” “Creating linkers that respond to enzymes overexpressed in cancer cells would move the industry further along”

#AVCT On trend.

#AVCT “With doxorubicin the payload is cleared quite slowly so we don’t need to keep it there longer in the form of AVA6000”

Next up is the AVA6103 abstract which, assuming Avacta have not requested it is withheld, gets released on Oct 9. The pipeline surely has to come before that. And with said pipeline must come an explanation as to how the pre-clinical candidates will be funded.

#AVCT The latest AVA6000 update, revealing that the tumour stroma is actively cleaving dox, is the most exciting yet - USP. The attached studies highlight the importance of the stroma in a tumour’s defence. How instrumental it is to its survival.